| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/19/2003 | EP1283836A2 Neuroprotective and anti-proliferative compounds |
| 02/19/2003 | EP1283735A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 02/19/2003 | EP1283723A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 02/19/2003 | EP1283722A1 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| 02/19/2003 | EP1283715A1 Modulaton of alpha-6 integrin-mediated responses |
| 02/19/2003 | EP1283712A1 Combination chemotherapy |
| 02/19/2003 | EP1283707A1 Polymerizable compositions and methods of use |
| 02/19/2003 | EP1283706A1 Dosage of transdermal delivery systems |
| 02/19/2003 | EP1283700A2 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 02/19/2003 | EP1283675A1 Methods of modulating the activity of mura |
| 02/19/2003 | EP1207878B1 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 02/19/2003 | EP1115729B1 Phosphonic acid derivatives as inhibitors of ptp-1b |
| 02/19/2003 | EP0959892B1 Use of pvp or povidone for reducing bowel distension |
| 02/19/2003 | EP0868175B1 Nitric oxide (no) synthase inhibitor to prevent type ii diabetes |
| 02/19/2003 | EP0732926B1 Pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors |
| 02/19/2003 | CN1398298A Non-endogenous, constitutively activated human G protein-coupled receptors |
| 02/19/2003 | CN1398189A Combination therapy of radiation and COX-2 inhibitor for treatment of neoplasia |
| 02/19/2003 | CN1398188A Boltuminum toxin pharmaceutical compsns |
| 02/19/2003 | CN1398185A Method to potentiate therapueutic efficiency of taxane and derivatives thereof |
| 02/19/2003 | CN1398181A Method and compsns. for treating inflammatory disease |
| 02/19/2003 | CN1397348A Novel target compsn. for diagnosis and treatment |
| 02/18/2003 | US6521759 Aminothiazole inhibitors of cyclin dependent kinases |
| 02/18/2003 | US6521755 Process for preparing 10,11-methanobenzosuberane derivatives |
| 02/18/2003 | US6521663 Aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors |
| 02/18/2003 | US6521659 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| 02/18/2003 | US6521644 Compositions for promoting growth |
| 02/18/2003 | US6521635 Inhibition of MXR transport by acridine derivatives |
| 02/18/2003 | US6521633 Treating NIDDM with RXR agonists |
| 02/18/2003 | US6521632 Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor |
| 02/18/2003 | US6521616 Administering taurolidine, taurultam, or a biologically active derivative; induces tumor cell death by apoptosis. |
| 02/18/2003 | US6521593 Using antagonists of integrins such as alpha v beta 3 and alpha v beta 5; inhibiting angiogenesis and vitronectin and tenascin mediated cell adhesion; inducing apoptosis |
| 02/18/2003 | US6521437 Human sphingosine lyase polypeptides |
| 02/18/2003 | US6521436 Gene expression; drug screening for antiarthritic agents; bone disorders |
| 02/18/2003 | US6521425 Screening and use of reagents which block or activate intein splicing utilizing natural or homologous exteins |
| 02/18/2003 | US6521422 Fhm, a novel member of the TNF ligand supergene family |
| 02/18/2003 | US6521417 Incubating permeabilized cells expressing mutant kinase with radiolabeled analog; cytolysis, separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| 02/18/2003 | US6521414 Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1 |
| 02/18/2003 | US6521407 Methods for determining chemosensitivity of cancer cells based upon expression of negative and positive signal transduction factors |
| 02/18/2003 | US6521262 Solid instant-release forms of administration and process for producing the same |
| 02/18/2003 | US6521259 Controlled release material comprising polyanhydrides, copolymers of lactic acid and glycolic acid, polylactic acid, polyglycolic acid, polyesters, polyorthoesters, proteins, polysaccharides; ouabain, digoxin |
| 02/18/2003 | US6521249 Feedstock for prepartum dairy cattle |
| 02/18/2003 | US6521242 Method for sequestration of nasal secretion skin irritants with facial tissue |
| 02/18/2003 | US6521241 That can bind a cytokine; clay, silica, titanium dioxide, and combinations thereof |
| 02/18/2003 | US6521240 That can bind a cytokine; clay, silica, titanium dioxide, and combinations thereof |
| 02/18/2003 | US6521213 Administering mixtures of lipids, surfactants, dispersants, propellants and drugs such as antibiotics, bactericides, viricides and fungicides to the ears; protective coatings that reduce surface tension of the air/liquid interfaces |
| 02/18/2003 | CA2218750C Topical treatment and/or prevention of sagging subcutaneous muscle and overlying cutaneous tissue using acetylcholine precursors and catecholamines |
| 02/18/2003 | CA2204210C Herb composition and an herbal plaster made from the same |
| 02/15/2003 | CA2397371A1 Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| 02/15/2003 | CA2392309A1 Neuropeptide receptor and uses thereof |
| 02/15/2003 | CA2392305A1 Adrenic acid receptor and uses thereof |
| 02/13/2003 | WO2003012441A1 Method for detecting modulators of notch signalling |
| 02/13/2003 | WO2003012432A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 02/13/2003 | WO2003012139A2 Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene |
| 02/13/2003 | WO2003012122A2 Crystallized structure of type iv collagen nc1 domain hexamer |
| 02/13/2003 | WO2003012105A2 Vegf isoform |
| 02/13/2003 | WO2003012104A1 Novel g protein-coupled receptor protein and dna thereof |
| 02/13/2003 | WO2003012089A2 Crystal structure of beta-site app cleaving enzyme (bace) and use thereof |
| 02/13/2003 | WO2003012072A2 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 02/13/2003 | WO2003012060A2 Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd |
| 02/13/2003 | WO2003012051A2 Inhibitor of dna methylation |
| 02/13/2003 | WO2003012030A2 Isoform-selective inhibitors and activators of pde3 cyclic |
| 02/13/2003 | WO2003011909A1 Binding agents with differential activity |
| 02/13/2003 | WO2003011907A2 Receptor, the use thereof, and mouse antibodies |
| 02/13/2003 | WO2003011906A2 Use of peptide fragments of the calcium channel α-1 subunit, optionally comprising mutations, for screening molecules of therapeutic interest |
| 02/13/2003 | WO2003011903A2 Identification of specific tumor antigens by means of the selection of cdna libraries with sera |
| 02/13/2003 | WO2003011902A1 Identification of specific tumour antigens by selection of cdna libraries with sera |
| 02/13/2003 | WO2003011879A1 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same |
| 02/13/2003 | WO2003011864A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a RECEPTOR AND THEIR USE AS MEDICAMENTS |
| 02/13/2003 | WO2003011862A1 Non-nucleoside reverse transcriptase inhibitors |
| 02/13/2003 | WO2003011855A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011854A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011842A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 02/13/2003 | WO2003011810A1 Method for the nitration of phenolic compounds |
| 02/13/2003 | WO2003011808A1 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 02/13/2003 | WO2003011384A1 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas |
| 02/13/2003 | WO2003011340A1 Medicament formulation for topical application in the therapy and prophylaxis of hyperhidrosis |
| 02/13/2003 | WO2003011337A1 MEDICINAL COMPOSITIONS CONTAINING Fc RECEPTOR Ϝ-CHAIN ACTIVATOR |
| 02/13/2003 | WO2003011317A1 Modulators of notch signalling for use in immunotherapy |
| 02/13/2003 | WO2003011316A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome |
| 02/13/2003 | WO2003011314A2 Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 02/13/2003 | WO2003011306A1 Sucralose formulations to mask unpleasant tastes |
| 02/13/2003 | WO2003011304A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity |
| 02/13/2003 | WO2003011303A1 Dermal therapy using phosphate derivatives of electron transfer agents |
| 02/13/2003 | WO2003011301A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| 02/13/2003 | WO2003011300A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 02/13/2003 | WO2003011282A1 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
| 02/13/2003 | WO2003011280A1 Use of vitamin e succinate and antiandrogen combination |
| 02/13/2003 | WO2003011277A2 Methods to mobilize progenitor/stem cells |
| 02/13/2003 | WO2003011274A2 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma |
| 02/13/2003 | WO2003011270A1 Agent for treating depressive disorders containing a local anesthetic agent |
| 02/13/2003 | WO2003011269A1 Agent for treating the symptoms of dementia disorders containing an additional local anesthetic agent |
| 02/13/2003 | WO2003011268A1 (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 02/13/2003 | WO2003011264A2 Betacarboline derivatives as gaba a-receptor-modulators having nmda-antagonistic activity for treating diseases of the central nervous system |
| 02/13/2003 | WO2003011251A1 Pulmonary formulation |
| 02/13/2003 | WO2003011243A1 Invert emulsion containing dhea |
| 02/13/2003 | WO2003011227A2 Taste masking composition |
| 02/13/2003 | WO2003011226A2 Products and drug delivery vehicles |
| 02/13/2003 | WO2003011210A2 Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 02/13/2003 | WO2003011114A2 Methods for treating prostatitis |
| 02/13/2003 | WO2003011008A2 Therapeutic delivery compositions and methods of use thereof |